- Home
- REFI vs ABEO Comparison
REFI vs ABEO Comparison
Compare REFI & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | ABEO |
|---|---|---|
| Founded | 2021 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 280.2M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | REFI | ABEO |
|---|---|---|
| Price | $12.30 | $4.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $18.75 |
| AVG Volume (30 Days) | 123.8K | ★ 1.3M |
| Earning Date | 03-12-2026 | 03-17-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ 1.68 | 1.01 |
| Revenue | ★ $48,857,628.00 | $2,998,000.00 |
| Revenue This Year | $19.62 | $1,276.65 |
| Revenue Next Year | $10.79 | $112.53 |
| P/E Ratio | $7.42 | ★ $4.50 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $11.62 | $3.93 |
| 52 Week High | $15.49 | $7.54 |
Technical Indicators
Market Signals| Indicator | REFI | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 33.98 |
| Support Level | $12.23 | $4.00 |
| Resistance Level | $12.46 | $5.62 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 54.83 | 10.05 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.